Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
N Engl J Med ; 384(20): 1910-1920, 2021 05 20.
Article in English | MEDLINE | ID: mdl-34010530

ABSTRACT

BACKGROUND: The effectiveness of endovascular therapy in patients with stroke caused by basilar-artery occlusion has not been well studied. METHODS: We randomly assigned patients within 6 hours after the estimated time of onset of a stroke due to basilar-artery occlusion, in a 1:1 ratio, to receive endovascular therapy or standard medical care. The primary outcome was a favorable functional outcome, defined as a score of 0 to 3 on the modified Rankin scale (range, 0 to 6, with 0 indicating no disability, 3 indicating moderate disability, and 6 indicating death) at 90 days. The primary safety outcomes were symptomatic intracranial hemorrhage within 3 days after the initiation of treatment and mortality at 90 days. RESULTS: A total of 300 patients were enrolled (154 in the endovascular therapy group and 146 in the medical care group). Intravenous thrombolysis was used in 78.6% of the patients in the endovascular group and in 79.5% of those in the medical group. Endovascular treatment was initiated at a median of 4.4 hours after stroke onset. A favorable functional outcome occurred in 68 of 154 patients (44.2%) in the endovascular group and 55 of 146 patients (37.7%) in the medical care group (risk ratio, 1.18; 95% confidence interval [CI], 0.92 to 1.50). Symptomatic intracranial hemorrhage occurred in 4.5% of the patients after endovascular therapy and in 0.7% of those after medical therapy (risk ratio, 6.9; 95% CI, 0.9 to 53.0); mortality at 90 days was 38.3% and 43.2%, respectively (risk ratio, 0.87; 95% CI, 0.68 to 1.12). CONCLUSIONS: Among patients with stroke from basilar-artery occlusion, endovascular therapy and medical therapy did not differ significantly with respect to a favorable functional outcome, but, as reflected by the wide confidence interval for the primary outcome, the results of this trial may not exclude a substantial benefit of endovascular therapy. Larger trials are needed to determine the efficacy and safety of endovascular therapy for basilar-artery occlusion. (Funded by the Dutch Heart Foundation and others; BASICS ClinicalTrials.gov number, NCT01717755; Netherlands Trial Register number, NL2500.).


Subject(s)
Endovascular Procedures , Fibrinolytic Agents/therapeutic use , Stroke/surgery , Thrombectomy/methods , Vertebrobasilar Insufficiency/complications , Aged , Arterial Occlusive Diseases/complications , Basilar Artery/diagnostic imaging , Confidence Intervals , Female , Humans , Intention to Treat Analysis , Male , Middle Aged , Severity of Illness Index , Single-Blind Method , Stroke/drug therapy , Stroke/etiology , Stroke/mortality , Thrombolytic Therapy , Time-to-Treatment , Treatment Outcome
2.
N Engl J Med ; 382(24): 2316-2326, 2020 06 11.
Article in English | MEDLINE | ID: mdl-32521133

ABSTRACT

BACKGROUND: Randomized trials involving patients with stroke have established that outcomes are improved with the use of thrombectomy for large-vessel occlusion. These trials were performed in high-resource countries and have had limited effects on medical practice in low- and middle-income countries. METHODS: We studied the safety and efficacy of thrombectomy in the public health system of Brazil. In 12 public hospitals, patients with a proximal intracranial occlusion in the anterior circulation that could be treated within 8 hours after the onset of stroke symptoms were randomly assigned in a 1:1 ratio to receive standard care plus mechanical thrombectomy (thrombectomy group) or standard care alone (control group). The primary outcome was the score on the modified Rankin scale (range, 0 [no symptoms] to 6 [death]) at 90 days. RESULTS: A total of 300 patients were enrolled, including 79 who had undergone thrombectomy during an open-label roll-in period. Approximately 70% in the two groups received intravenous alteplase. The trial was stopped early because of efficacy when 221 of a planned 690 patients had undergone randomization (111 to the thrombectomy group and 110 to the control group). The common odds ratio for a better distribution of scores on the modified Rankin scale at 90 days was 2.28 (95% confidence interval [CI], 1.41 to 3.69; P = 0.001), favoring thrombectomy. The percentage of patients with a score on the modified Rankin scale of 0 to 2, signifying an absence of or minor neurologic deficit, was 35.1% in the thrombectomy group and 20.0% in the control group (difference, 15.1 percentage points; 95% CI, 2.6 to 27.6). Asymptomatic intracranial hemorrhage occurred in 51.4% of the patients in the thrombectomy group and 24.5% of those in the control group; symptomatic intracranial hemorrhage occurred in 4.5% of the patients in each group. CONCLUSIONS: In this randomized trial conducted in the public health care system of Brazil, endovascular treatment within 8 hours after the onset of stroke symptoms in conjunction with standard care resulted in better functional outcomes at 90 days than standard care alone. (Funded by the Brazilian Ministry of Health; RESILIENT ClinicalTrials.gov number, NCT02216643.).


Subject(s)
Stroke/surgery , Thrombectomy , Adult , Aged , Aged, 80 and over , Brazil , Combined Modality Therapy , Endovascular Procedures , Female , Fibrinolytic Agents/therapeutic use , Humans , Intracranial Hemorrhages/etiology , Male , Middle Aged , Severity of Illness Index , Single-Blind Method , Stroke/drug therapy , Stroke/mortality , Thrombectomy/adverse effects , Thrombectomy/methods , Time-to-Treatment , Tissue Plasminogen Activator/therapeutic use , Treatment Outcome , Young Adult
3.
Lancet Neurol ; 18(7): 674-683, 2019 07.
Article in English | MEDLINE | ID: mdl-31029579

ABSTRACT

The large and increasing burden of stroke in Latin American countries, and the need to meet the UN and WHO requirements for reducing the burden from non-communicable disorders (including stroke), brought together stroke experts and representatives of the Ministries of Health of 13 Latin American countries for the 1st Latin American Stroke Ministerial meeting in Gramado, Brazil, to discuss the problem and identify ways of cooperating to reduce the burden of stroke in the region. Discussions were focused on the regional and country-specific activities associated with stroke prevention and treatment, including public stroke awareness, prevention strategies, delivery and organisation of care, clinical practice gaps, and unmet needs. The meeting culminated with the adoption of the special Gramado Declaration, signed by all Ministerial officials who attended the meeting. With agreed priorities for stroke prevention, treatment, and research, an opportunity now exists to translate this Declaration into an action plan to reduce the burden of stroke.


Subject(s)
Cost of Illness , Health Policy , Stroke/epidemiology , Humans , Incidence , Latin America/epidemiology , Prevalence , Stroke/mortality
4.
Arq. bras. med ; 59(6): 397-406, dez. 1985. tab, ilus
Article in Portuguese | LILACS | ID: lil-30254

ABSTRACT

O comprometimento do SNC foi analisado em 19 pacientes com AIDS, sendo 11 hemofílicos, seis homossexuais e dois bissexuais. Onze enfermos da série apresentaram toxoplasmose do SNC. O diagnóstico foi estabelecido por pesquisa do IgG e IgM específicas no soro e no líquor, por tomografia computadorizada, biopsia cerebral e exame histopatológico post-mortem. Desde 11 pacientes com infecçäo neurológica central pelo T. gondii, apenas cinco beneficiaram-se, ainda com vida, do diagnóstico patológico, recebendo, portanto, tratamento específico e recuperando-se desta doença. Os autores mostram que o aparecimento de um grande número de casos desta condiçäo patológica num curto espaço de tempo caracteriza surto epidêmico. Argumentam ainda que o acometimento do SNC pelo T. gondii deve ser suspeitado em todo enfermo com AIDS que apresente sinais de envolvimento neurológico, enfatizando que a toxoplasmose do SNC pode ser a primeira expressäo da síndrome


Subject(s)
Child , Adolescent , Adult , Middle Aged , Humans , Male , Central Nervous System Diseases/complications , Pyrimethamine/therapeutic use , Acquired Immunodeficiency Syndrome/complications , Toxoplasmosis/complications , Brazil , Drug Therapy, Combination , Sulfadiazine/therapeutic use , Toxoplasmosis/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...